Astal Laboratories Limited

**ASTAL LABORATORIES LIMITED**
CIN: L74120UP1993PLC015605
Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

**Date: 13-11-2026**

To,
*The Deputy Manager*
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001

**Subject: Outcome of Board Meeting held on Friday, 13th November, 2026 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) (LODR) Regulations, 2015.**
**Ref.: Scrip Code: 512600**
**Security Id: ASTALLTD**

**Respected Sir/Madam,**

This is to inform that Board of Directors of the Company in its meeting held on Friday **13th November, 2026** at the corporate office of the company i.e., House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, *Telangana, India, 500032, which commenced at 5:00 P.M. has considered and approved:*

1. The Unaudited Standalone Financial Results of the company for the quarter and half year ended 30th September, 2026 along with the limited review report of the auditors thereon.

2. The Unaudited Consolidated Financial Results of the company for the quarter and half year ended 30th September, 2026 along with the limited review report of the auditors thereon.

The Meeting was concluded at 05:50 P.M. with the vote of thanks.

We request you to take the aforesaid information on record for dissemination through your website.

Thanking you
Yours sincerely,

**For Astal Laboratories Limited**

**Mahendra Kumar**
**(Company Secretary & Compliance Officer)**
**Membership No.: A71224**

SATHULURI & CO.
CHARTERED ACCOUNTANTS

**Limited Review Report on Standalone Unaudited Quarterly Financial Results of Astal Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,
Board of Directors
**Astal Laboratories Limited**

We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **Astal Laboratories Limited** for the quarter and half year ended on 30th September, 2026, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation,2015, (the Regulation) as amended, (the "Listing Regulations').

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Off: 11-13-1377/2, Flat No. 401, City Centre Complex, Margadarshi Colony, Kothapet, Hyderabad-500035.
Ph: 9391686797 Email: casathuluri93@gmail.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Sathuluri & Co.**
Chartered Accountants
(FRN. No.006383S)




**CA S S Prakash**
Partner
M.No. 202710

**UDIN : 26202710AFAIFT2589**

Place: Hyderabad
Date : 13-11-2026

Astal Laboratories Limited

# ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2026

Rs. (In Lakhs)

| Sr. No | Particulars | 3 Months ended | Preceding 3 Months ended | Corsponding 3 Months Ended Ended in Previous Year | Year to Date Figures for Current Period Ended | Year to date figures for previous Period ended | Year to date figures for Previous year ended |
|---|---|---|---|---|---|---|---|
| | | 30.09.2026 | 30.06.2026 | 30.09.2025 | 30.09.2026 | 30.09.2025 | 31.03.2026 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1 | **Revenue** | | | | | | |
| | a) From operations | 4,072.37 | 3,951.41 | 3,751.64 | 8,023.78 | 6,284.30 | 15,599.53 |
| | b) Other Income (Refer to Note No.3) | 15.38 | 3.21 | 3.27 | 18.59 | 8.88 | 19.16 |
| | **Total Revenue** | **4,087.75** | **3,954.62** | **3,754.91** | **8,042.37** | **6,293.18** | **15,618.68** |
| 2 | **Expenses** | | | | | | |
| | (a) Cost of Material Consumed | 3,822.03 | 4,081.52 | 3,908.02 | 7,903.56 | 6,216.23 | 15,288.45 |
| | (b) Purchases of stock-in-trade | - | - | - | - | - | - |
| | (c) Change in inventories of finished goods, work-in-progress and stock-in-trade | (452.17) | (799.50) | (626.03) | (1,251.67) | (787.66) | (1,401.56) |
| | | - | | - | | - | |
| | (d) Employees Benefits expenses | 42.74 | 61.82 | 41.83 | 104.55 | 86.55 | 211.26 |
| | (e) Finance Cost | 39.11 | 32.79 | 30.91 | 71.89 | 60.99 | 140.91 |
| | (f) Depreciation amortization expenses | 18.46 | 17.74 | 12.24 | 36.20 | 24.25 | 68.84 |
| | (g) Other Expenses | 108.67 | 64.60 | 40.94 | 173.28 | 66.53 | 224.23 |
| | **Total Expenses** | **3,578.84** | **3,458.97** | **3,407.92** | **7,037.81** | **5,666.90** | **14,532.12** |
| 3 | **Profit from ordinary activities before exceptonal Items (1 - 2)** | 508.91 | 495.65 | 346.99 | 1,004.56 | 626.28 | 1,086.56 |
| 4 | **Exceptional Items - Income/ (Expenses)** | - | - | - | - | - | - |
| 5 | ***Profit from ordinary* activities before tax (3 - 4)** | 508.91 | 495.65 | 346.99 | 1,004.56 | 626.28 | 1,086.56 |
| 6 | Tax Expenses | | | | | | |
| | (a) Current Tax | 145.58 | 103.13 | 90.41 | 248.71 | 136.02 | 258.84 |
| | (b) Deferred Tax | (15.79) | 21.83 | (1.68) | 6.05 | 23.03 | 16.17 |
| 7 | **Profit/(Loss) for the period (5 -6)** | 379.12 | 370.69 | 258.26 | 749.80 | 467.22 | 811.55 |
| 8 | A (i) Items that will not be reclassified to profit or loss (net of tax) | - | - | - | - | - | - |

Astal Laboratories Limited

**ASTAL LABORATORIES LIMITED**
CIN: L74120UP1993PLC015605
Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | (ii) Income Tax relating to items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| | B (i) Items that will not be reclassified to profit or loss (net of tax) | - | - | - | - | - | - |
| | (ii) Income Tax relating to items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| 9 | **Total Comprehensive Income, net of tax (7 + 8)** | 379.12 | 370.69 | 258.26 | 749.80 | 467.22 | 811.55 |
| 10 | **Paid up equity share capital** (Face Value of Rs.10/- each) | 4,379.89 | 4,379.89 | 1,077.00 | 4,379.89 | 1,077.00 | 4,223.11 |
| 11 | **Earning per share** (of Rs.10/-each) not annualised | | | | | | |
| | **(a) Basic** | **0.866** | **0.861** | **2.395** | **1.726** | **4.338** | **4.757** |
| | **(b) Diluted** | **0.862** | **0.857** | **1.972** | **1.719** | **3.568** | **4.310** |

**Notes:**

| | |
|---|---|
| 1 | The above Unaudited Standalone Financial Results of the company for the quarter and half year ended September 30, 2026 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 13th November, 2026. |
| 2 | The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). |
| 3 | Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period. |
| 4 | These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016 |
| 5 | The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results. |
| 6 | The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website https://astallabs.com/ |
| 7 | The Company has one Material Wholly Owned Subsidiary Company as on September 30, 2026. |

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 13/11/2026

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466

Astal Laboratories Limited

# ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

## STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30,2026

(Rs. In lakhs.)

| | PARTICULARS | As at 30th September, 2026 (Unaudited) | As at 31-March 2026 (Audited) |
|---|---|---|---|
| | **ASSETS** | | |
| 1 | **Non - current assets** | | |
| (a) | Property, plant and equipment | 1123.22 | 1135.84 |
| (b) | Right-of-use-asset | 65.08 | 74.85 |
| (c) | Capital work in progress | | |
| (d) | Investment property | | |
| (e) | Intangible assets-Good will | | |
| (f) | Financial assets | | |
| | (i) Investment in Sriven Pharmachem India Pvt Ltd | 27716.95 | 27716.95 |
| | (ii) Loans | 389.81 | 409.26 |
| | (iii) Other financial assets | | |
| | (iv) Balance with Banks | | |
| (g) | Deferred tax Assets (Net) | | |
| (h) | Other Non-current assets | | 0.00 |
| | **Total non-currrent assets** | **29295.06** | **29336.89** |
| 2 | **Current assets** | | |
| (a) | Inventories | 4721.37 | 2877.54 |
| (b) | **Financial assets** | | |
| | (i) Investments | | |
| | (ii) Trade receivables | 7278.43 | 7230.17 |
| | (iii) Cash and cash equivalents | 342.35 | 353.34 |
| | (iv) Other balances with banks | | |
| | (v) Loans | | |
| | (vi) Other financial assets | 10.53 | 10.53 |
| (c) | Other Current assests | 33.95 | 148.72 |
| | **Total current assets** | **12386.63** | **10620.31** |
| | **TOTAL ASSETS** | **41681.70** | **39957.20** |
| | **EQUITY AND LIABILITIES** | | |
| 1 | **Equity** | | |
| (a) | Share capital | 4381.45 | 4223.12 |
| (b) | Other equity | 29529.67 | 28493.20 |
| | **Total Equity** | **33911.12** | **32716.32** |
| 2 | **Non-current liabilities** | | |
| (a) | Financial liabilities | | |
| | (i) Long-term borrowings | 250.08 | 36.59 |
| | (ii) Deferred tax liabilities (net) | 34.08 | 28.03 |
| | (iii) Lease Liabilities | | |
| | (iv) Other financial liabilities | | |

ASTAL LABORATORIES LIMITED

Astal Laboratories Limited

**ASTAL LABORATORIES LIMITED**
CIN: L74120UP1993PLC015605
Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

| | | | |
|---|---|---|---|
| (b) | Provisions | | |
| (c) | Other Non Current liabilities | | |
| | **Total non-current liabilities** | **284.16** | **64.62** |
| 3 | **Current liabilities** | | |
| (a) | Financial liabilities | | |
| | (i) Borrowings | 1375.06 | 1159.20 |
| | (ii) Lease Liabilities | | |
| | (iii) Trade payables | 5393.41 | 5406.67 |
| | (iv) Other financial liabilities | 72.92 | 80.99 |
| (b) | Provisions | | |
| (c) | Other current Liabilities | 645.03 | 529.40 |
| | **Total current liabilities** | **7486.42** | **7176.26** |
| | **Total Liabilities** | **7770.58** | **7240.88** |
| | TOTAL EQUITY AND LIABILITIES | **41681.70** | **39957.20** |

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 13/11/2026

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466

Astal Laboratories Limited

# ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

## STATEMENT OF STANDALONE CASH FLOW STATEMENT AS AT SEPTEMBER 30, 2026

| | PARTICULARS | 30th September, 2026 Amount (Rs. In Lakhs) (Unaudited) | 31st March, 2026 Amoun (Rs. In Lakhs) (Audited) |
|---|---|---|---|
| | | | |
| A. | **CASH FLOW FROM OPERATING ACTIVITIES: -** | | |
| | Net Profit/(Loss) before tax as per statement of Profit & Loss | 1,004.56 | 1,086.56 |
| | Adjustment for: - | | |
| | Depreciation | 36.20 | 68.84 |
| | Finance Cost | 71.89 | 140.91 |
| | Interest Income | (18.59) | (19.16) |
| | *Operating Profit before working capital changes.* | 1,094.07 | 1,277.16 |
| | Adjustment for: - | | |
| | Changes in Trade Receivables | (48.26) | (4,463.77) |
| | Changes in Trade Payables | (13.26) | 4,329.18 |
| | Changes in Inventory | (1,843.83) | (1,401.56) |
| | Changes in Other Current Assets | 114.77 | (0.19) |
| | Changes in Other Non-Current assets | | (0.53) |
| | Changes in Other Current liabilities | (133.07) | 54.21 |
| | Cash generated form operations | (829.58) | (205.50) |
| | Taxes paid (Net) | - | (102.08) |
| | **Net cash generated from / (used in) Operating Activities** | **(829.58)** | **(307.57)** |
| | | | |
| B. | **CASH FLOW FROM INVESTING ACTIVITIES: -** | | |
| | Interest Income | 18.59 | 19.16 |
| | Purchase of Fixed Assets | (13.82) | (40.72) |
| | Investment in Sriven Pharma-Cash Consideration | - | (29.63) |
| | (Issue) / Recovery of Loans and advances | 19.45 | (0.00) |
| | Fixed Deposit with Banks | (35.98) | (77.28) |
| | **Net cash from Investing Activities** | **(11.77)** | **(128.47)** |
| | | | |
| C. | **CASH FLOW FROM FINANCING ACTIVITIES: -** | | |
| | Interest Expense | (68.05) | (131.95) |
| | Interest Expense on Lease Liability | (3.85) | (8.97) |
| | Principal payment on Lease Liability | (8.07) | (13.38) |
| | Long Term Borrowings Taken | 220.22 | - |
| | Long Term Borrowings Repaid | (6.73) | (9.02) |
| | Issue of Shares | | - |
| | Security Premium | | - |
| | Share Warrets Amount received | 444.99 | 617.98 |
| | **Net cash from (used in) Financing Activities** | **578.52** | **454.67** |
| | | | |
| | **Net (Decrese)/Increase in Cash & Cash Equivalent (A+B+C)** | **(262.83)** | **18.62** |

Astal Laboratories Limited

**ASTAL LABORATORIES LIMITED**
CIN: L74120UP1993PLC015605
Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

| | | | |
|---|---|---|---|
| | **Opening Balance of Cash & Cash Equivalents** | **(1,077.78)** | **(1,096.40)** |
| | *Cash on hand* | 7.60 | 0.02 |
| | Balance With Banks | 62.00 | 172.99 |
| | Bank overdrafts and cash credit facility (secured)* | (1,147.39) | (1,269.40) |
| | **Closing Balance of Cash & Cash Equivalents** | **(1,340.61)** | **(1,077.78)** |
| | Cash on hand | 7.23 | 7.60 |
| | Balance With Banks | 15.4 | 62.0 |
| | Bank overdrafts and cash credit facility (secured)* | (1,363.2) | (1,147.4) |
| | | | |
| 1 | Figures in brackets represent cash out flows. | | |
| 2 | The above Cash Flow statement has been prepared under the "Indirect Method" set out in Accounting Standard (Ind AS-7) on Statement of Cash flows issued by the Institute of Chartered Accountants of India. | | |
| 3 | *Previous year`s comparative have been reclassified to confirm with current year's presentation wherever applicable.* | | |
| *4 | Bank overdrafts and cash credit facility are part of cash management system of the Company. Hence, considered as part of cash and cash equivalents | | |

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 13/11/2026

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466

SATHULURI & CO.
CHARTERED ACCOUNTANTS

**Limited Review Report on Consolidated Unaudited Quarterly Financial Results of Astal Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,
Board of Directors
**Astal Laboratories Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Astal Laboratories Limited** (the "Holding Company") and its subsidiary (the "Holding Company" and its subsidiary together referred to as "the Group"), for the quarter and half year ended 30th September, 2026, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



Off: 11-13-1377/2, Flat No. 401, City Centre Complex, Margadarshi Colony, Kothapet, Hyderabad-500035.
Ph: 9391686797 Email: casathuluri93@gmail.com

4. The Statement includes the results of the following Subsidiary entities:

   (i) Sriven Pharmachem India Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial results of One Wholly Owned Subsidiary included in the consolidated unaudited financial results, whose interim financial results reflect total revenue of Rs. **6,732.36** Lakhs, Rs. **12,885.13** Lakhs and Rs. **9,418.27** Lakhs, total net profit after tax of Rs. **597.92** Lakhs, Rs. **1169.40** Lakhs and Rs. **659.40** Lakhs and total comprehensive income of Rs. **597.92** Lakhs, Rs. **1169.40** Lakhs and Rs. **659.40** Lakhs, for the quarter and half year ended September 30, 2026 and for the period from 14th January to March 31, 2026 respectively as considered in the consolidated unaudited financial results, and

   Total Assets of Rs. **20,474.43** Lakhs and Rs. **19,313.92** Lakhs for the half year ended September 30, 2026 and from 14th January to March 31, 2026 respectively as considered in the consolidated unaudited financial statements, and

   Net cash outflows of Rs.**33.61** Lakhs, Rs. **488.06** Lakhs for the half year ended September 30, 2026 and the period from 14-01-2026 to 31-03-2026 respectively as considered in the consolidated unaudited Cash flow statement.



These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

**For Sathuluri & Co.**
Chartered Accountants
(FRN. No.006383S)

**CA S S Prakash**
Partner
M.No. 202710

**UDIN : 26202710MYVXZW3895**

Place: Hyderabad
Date : 13-11-2026

Astal Laboratories Limited

# ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

## STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2026

Rs. (In Lakhs)

| Sr. No | Particulars | 3 Months ended | Preceding 3 Months ended | Corsponding 3 Months Ended Ended in Previous Year | Year to Date Figures for Current Period Ended | Year to Date Figures for Previous Period Ended | Year to date figures for Previous year ended |
|---|---|---|---|---|---|---|---|
| | | 30.09.2026 | 30.06.2026 | 30.09.2025 | 30.09.2026 | 30.09.2025 | 31.03.2026 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1 | **Revenue** | | | | | | |
| | a) From operations | 10,794.28 | 10,093.58 | 3,751.64 | 20,887.86 | 6,284.30 | 24,912.73 |
| | b) Other Income (Refer to Note No.3) | 25.83 | 13.81 | 3.27 | 39.63 | 8.88 | 22.15 |
| | **Total Revenue** | **10,820.11** | **10,107.39** | **3,754.91** | **20,927.49** | **6,293.18** | **24,934.88** |
| 2 | **Expenses** | | | | | | |
| | (a) Cost of Material Consumed | 8,646.31 | 10,011.74 | 3,908.02 | 18,658.05 | 6,216.23 | 22,490.57 |
| | (b) Purchases of stock-in-trade | - | - | - | - | - | - |
| | (c) Change in inventories of finished goods, work-in-progress and stock-in-trade | (279.80) | (1,739.97) | (626.03) | (2,019.77) | (787.66) | (588.57) |
| | | - | - | - | - | - | - |
| | (d) Employees Benefits expenses | 276.48 | 314.82 | 41.83 | 591.30 | 86.55 | 502.15 |
| | (e) Finance Cost | 133.57 | 117.60 | 30.91 | 251.17 | 60.99 | 203.25 |
| | (f) Depreciation amortization expenses | 88.41 | 86.01 | 12.24 | 174.42 | 24.25 | 122.82 |
| | (g) Other Expenses | 421.99 | 282.18 | 40.94 | 704.17 | 66.53 | 431.62 |
| | **Total Expenses** | **9,286.95** | 9,072.38 | **3,407.92** | **18,359.33** | **5,666.90** | **23,161.85** |
| 3 | **Profit from ordinary activities before exceptonal Items (1- 2)** | **1,533.15** | **1,035.01** | **346.99** | **2,568.16** | **626.28** | **1,773.03** |
| 4 | **Exceptional Items - Income/ (Expenses)** | - | - | - | - | - | - |
| 5 | **Profit from ordinary activities before tax (3 - 4)** | **1,533.15** | **1,035.01** | **346.99** | **2,568.16** | **626.28** | **1,773.03** |
| 6 | Tax Expenses | | | | | | |
| | (a) Current Tax | 500.91 | 119.70 | 90.41 | 620.61 | 136.02 | 268.04 |
| | (b) Deferred Tax | 55.20 | (26.86) | (1.68) | 28.34 | 23.03 | 34.05 |
| 7 | **Profit/(Loss) for the period (5 -6)** | **977.04** | **942.17** | **258.26** | **1,919.21** | **467.22** | **1,470.94** |
| 8 | A (i) Items that will not be reclassified to profit or loss (net of tax) | - | - | - | - | - | - |

ASTAL LABORATORIES LIMITED

Astal Laboratories Limited

**ASTAL LABORATORIES LIMITED**
CIN: L74120UP1993PLC015605
Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | (ii) Income Tax relating to items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| | B (i) Items that will not be reclassified to profit or loss (net of tax) | - | - | - | - | - | - |
| | (ii) Income Tax relating to items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| 9 | **Total Comprehensive Income, net of tax (7 + 8)** | **977.04** | **942.17** | **258.26** | **1,919.21** | **467.22** | **1,470.94** |
| 10 | **Paid up equity share capital** (Face Value of Rs.10/- each) | 4,379.89 | 4,379.89 | 1,077.00 | 4,379.89 | 1,077.00 | 4,223.11 |
| 11 | **Earning per share** (of Rs.10/-each) not annualised | | | | | | |
| | **(a) Basic** | **2.231** | **2.188** | **2.395** | **4.419** | **4.338** | **8.620** |
| | **(b) Diluted** | **2.221** | **2.178** | **1.972** | **4.400** | **3.568** | **7.810** |

NOTES:

| | |
|---|---|
| 1 | The above Unaudited Consolidated Financial Results of the company for the quarter and half year ended September 30, 2026 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 13th November, 2026. |
| 2 | The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). |
| 3 | Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period. |
| 4 | These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016 |
| 5 | The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results. |
| 6 | The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website https://astallabs.com/ |
| 7 | The Company has one Material Wholly Owned Subsidiary Company as on September 30, 2026. The requirement of Consolidation for the corresponding period ended and Year-to-Date Figures for Previous Period Ended as on 30.09.2025 was not applicable. |

**//By the order of the Board//**
**For Astal Laboratories Limited**

**Place: Hyderabad**
**Date: 13/11/2026**

**SUDHEER KARNA KANKANALA**
**(Wholetime Director)**
**DIN: 07591466**

Astal Laboratories Limited

# ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

## STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026

(Rs. In Lakhs)

| PARTICULARS | | As at 30th Sep 2026 (Unaudited) | As at 31-March 2026 (Audited) |
|---|---|---|---|
| | **ASSETS** | | |
| 1 | **Non - current assets** | | |
| (a) | Property, plant and equipment | 6,208.95 | 6,371.10 |
| (b) | Right-of-use-asset | 65.08 | 74.85 |
| (c) | Intangible assets-Good will | 20,320.17 | 20,320.17 |
| (d) | Financial assets | | |
| | (i) Loans | 389.81 | 409.26 |
| | (ii) Balance with Banks | 379.56 | 343.59 |
| (e) | *Other Non-current aasets* | 39.05 | 39.67 |
| | **Total non-currrent assets** | **27,402.62** | **27,558.64** |
| 2 | **Current assets** | - | - |
| (a) | Inventories | 9,932.42 | 6,752.31 |
| (b) | Financial assets | - | - |
| | (i) Trade receivables | 15,969.35 | 15,689.58 |
| | (ii) Cash and cash equivalents | 25.15 | 70.26 |
| (c) | Other Current assests | 1,406.80 | 1,803.54 |
| | ***Total current assets*** | **27,333.72** | **24,315.70** |
| | **TOTAL ASSETS** | **54,736.34** | **51,874.34** |
| | **EQUITY AND LIABILITIES** | | |
| 1 | **Equity** | | |
| (a) | Share capital | 4,381.45 | 4,223.12 |
| (b) | Other equity | 31,358.40 | 29,152.53 |
| | **Total Equity** | **35,739.84** | **33,375.65** |
| 2 | **Non-current liabilities** | | |
| (a) | Financial liabilities | | |
| | (i) Long-term borrowings | 1,912.38 | 1,864.15 |
| | *(ii) Deferred tax liabilities (net)* | 114.58 | 86.24 |
| | (iii) Lease Liabilities | 56.71 | 64.78 |
| (b) | Provisions | - | - |
| (c) | Other Non Current liabilities | - | - |
| | **Total non-current liabilities** | **2,083.67** | **2,015.17** |
| 3 | **Current liabilities** | | |
| (a) | Financial liabilities | | |
| | (i) Borrowings | 3,328.53 | 3,044.18 |
| | (ii) Lease Liabilities | 16.21 | 16.21 |
| | (iii) Trade payables | 12,182.17 | 12,435.32 |
| | (iv) Other financial liabilities | - | - |
| (b) | Provisions | - | - |
| (c) | Other current Liabilities | 1,385.92 | 987.81 |

Astal Laboratories Limited

**ASTAL LABORATORIES LIMITED**

**CIN: L74120UP1993PLC015605**

**Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301**
**Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032**
**SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India**
**Email: meil100@rediffmail.com: Mob. No: 6302730973, Website:** https://astallabs.com/

| | | | |
|---|---|---|---|
| | Total current liabilities | 16,912.83 | 16,483.52 |
| | Total Liabilities | 18,996.49 | 18,498.69 |
| | TOTAL EQUITY AND LIABILITIES | 54,736.34 | 51,874.34 |

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 13/11/2026

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466

Astal Laboratories Limited

# ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

## STATEMENT OF STANDALONE UNAUDITED CASH FLOW AS ON SEPTEMBER 30, 2026

(Rs. In Lakhs)

| | PARTICULARS | 30th September, 2026 (Unaudited) | 31st March, 2026 (Audited) |
|---|---|---|---|
| A) | **CASH FLOW FROM OPERATING ACTIVITIES** | | |
| | **Profit before tax for the year** | | |
| | Net Profit before exceptional and tax as Statement Profit & Loss (Increase in Reserves) | 2,568.16 | 1,773.03 |
| | Adjusted for :- | - | - |
| | Finance Cost | 251.17 | 203.25 |
| | Depreciation and amortisation | 174.42 | 122.82 |
| | Bad debts written off | | |
| | Loss on sale/scrappin of Property, Plant and Equipments | (10.04) | - |
| | Finance Cost | | |
| | Interest income | (29.59) | (22.15) |
| | **Operating Profit before Working Capital Changes** | **2954.12** | **2076.95** |
| | Adjusted for changes in working capital | | |
| | Increase /(Decrease) in Trade Payables | (230.15) | 4,534.52 |
| | Increase /(Decrease) in Borrowings | | |
| | Increase /(Decrease) in Other financial liabilities | | |
| | Increase /( Decrease) in Other current liabilities | (222.49) | 332.79 |
| | Increase /( Decrease) in Other Non-current liabilities | | |
| | Increase /( Decrease) in Provisions (except IT) | | |
| | Increase /( Decrease) in Current Tax Liabilities (Net) | | |
| | (Increase)/Decrease in Inventory | (3,180.11) | (588.56) |
| | (Increase)/Decrease in Trade receivables | (302.78) | (7,934.07) |
| | (Increase)/Decrease in Others current financial assets | 0.63 | (29.14) |
| | (Increase)/Decrease in Other current assets | 396.75 | 1,353.23 |
| | (Increase) / Decrease in Non-current Financial Assets | | (1,413.52) |
| | Consolidation adjustment | | |
| | **Cash Generated From Operations** | **(584.04)** | **(1,667.80)** |
| | **Net Cash used in Operating Activities Before Extraordinary Items** | | |
| | Less: - Extraordinary Items | | |
| | **Cash Generated From Operations** | **(584.04)** | **(1,667.80)** |
| | Less: - Taxes Paid | - | (102.08) |
| | **Net Cash Flow/(used)From Operating Activities (A)** | **(584.04)** | **(1,769.88)** |
| | | | |
| B) | **CASH FLOW FROM INVESTING ACTIVITIES** | | |
| | (Increase) / Decrease in Other Non-Current assets | - | 10.00 |
| | Purchase of Fixed Assets | (77.35) | (139.26) |
| | Investment in Sriven Pharma-Cash Consideration | - | (29.63) |
| | (Issue) / Recovery of Loans and advances | 19.45 | - |
| | Deposits with Bank | (35.98) | (77.28) |
| | Interest income | 29.59 | 19.16 |
| | Proceeds From Sales/written off of Fixed Assets | 84.88 | - |

Astal Laboratories Limited

**ASTAL LABORATORIES LIMITED**

**CIN: L74120UP1993PLC015605**

**Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301**
**Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032**
**SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India**
**Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/**

| | | | |
|---|---|---|---|
| | **Net Cash Flow/(used) in Investing Activities (B)** | **20.59** | **(217.01)** |
| C) | **CASH FLOW FROM FINANCING ACTIVITIES** | | |
| | Procurement of Borrowings | 253.25 | - |
| | Interest Expense on Lease Liability | (3.85) | - |
| | Lease Lability | (8.07) | (22.34) |
| | Repayment of Borrowings | (171.99) | (143.34) |
| | Interest paid | (247.32) | (194.29) |
| | Shares/Warrents Amount Received | 444.99 | 617.98 |
| | ***Net Cash Flow/(used) From Financing Activities C)*** | ***267.00*** | ***258.01*** |
| | | | |
| | **Net Increase/(Decrease) in Cash and Cash Equivalent (A+B+C)** | **(296.44)** | **(1,728.88)** |
| | | | |
| | Opening balance of Cash and Cash Equivalent | **(2,825.28)** | **(1,096.40)** |
| | Cash on hand | 7.64 | 0.02 |
| | Balance With Banks | 62.63 | 172.99 |
| | Bank overdrafts and cash credit facility (secured)* | (2,895.55) | (1,269.40) |
| | | | |
| | **Closing balance of Cash and Cash Equivalent** | **(3,121.72)** | **(2,825.28)** |
| | Cash on hand | 9.34 | 7.64 |
| | Balance With Banks | 15.81 | 62.63 |
| | Bank overdrafts and cash credit facility (secured)* | (3,146.87) | (2,895.55) |
| | | | |

The above Cash Flow Statement has been prepared under the Indirect Method ' as set out lnd AS - 7 "Statement of Cash Flows".

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 13/11/2026

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466